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Dengue is a potentially fatal acute febrile illness caused by 
any of four mosquito-transmitted dengue viruses (DENV-1 to 
DENV-4) belonging to the family Flaviviridae and endemic 
throughout the tropics. Competent mosquito vectors of DENV 
are present in approximately one half of all U.S. counties. To 
describe epidemiologic trends in travel-associated and locally 
acquired dengue cases in the United States, CDC analyzed 
cases reported from the 50 states and District of Columbia 
to the national arboviral surveillance system (ArboNET). 
Cases are confirmed by detection of 1) virus RNA by reverse 
transcription–polymerase chain reaction (RT-PCR) in any 
body fluid or tissue, 2) DENV antigen in tissue by a validated 
assay, 3) DENV nonstructural protein 1 (NS1) antigen, or 
4) immunoglobulin M (IgM) anti-DENV antibody if the 
patient did not report travel to an area with other circulating 
flaviviruses. When travel to an area with other flaviviruses was 
reported, IgM-positive cases were defined as probable. During 
2010–2017, totals of 5,009 (93%) travel-associated and 378 
(7%) locally acquired confirmed or probable dengue cases were 
reported to ArboNET. Cases were equally distributed between 
males and females, and median age was 41 years. Eighteen 
(three per 1,000) fatal cases were reported, all among travel-
ers. Travelers should review country-specific recommendations 
(https://wwwnc.cdc.gov/travel/notices/watch/dengue-asia) for 
reducing their risk for DENV infection, including using insect 
repellent and staying in residences with air conditioning or 
screens on windows and doors.
DENV infection can be asymptomatic or cause disease rang-
ing from a febrile illness with headache, myalgia, arthralgia, 
and rash, to potentially fatal manifestation of severe dengue, 
including plasma leakage, hemorrhage, or severe organ impair-
ment. The four DENVs are endemic throughout the tropics 
and are common causes of acute febrile illness in travelers (1). 
Globally, the number of dengue cases doubled each decade 
from 1990 to 2013, reaching an estimated maximum of 390 
million (95% credible interval [CI]*  =  284–528) DENV 
infections in 2010, 96 million (95% CI = 67–136) of which 
resulted in symptomatic cases (2). An estimated average of 
13,600 (95% uncertainty interval [UI]†  =  4,200–34,700) 
persons die from dengue every year (3). The geographic range of 
dengue is expected to further expand as a result of rising world 
temperatures and urbanization (4). Infection with a DENV 
produces long-lasting immunity to that virus; however, persons 
later infected with another DENV can be at increased risk for 
developing severe dengue (5).
* Differs from a confidence interval; a credible interval is the interval in which 
an unobserved parameter has a given probability, dependent on the prior 
distribution.
† Another term for confidence interval.
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Although multiple behavioral, environmental, and ento-
mologic approaches have been implemented to control 
Aedes spp. mosquito populations, none has yet proven to be 
both sustainable and effective. No specific treatment for den-
gue exists. The first Food and Drug Administration–approved 
vaccine against dengue, Dengvaxia, is licensed for use in 
approximately 20 countries, and was recently approved for 
use in the United States in children aged 9–16 years who have 
laboratory evidence of prior DENV infection and who live in 
areas with endemic DENV (6). The Advisory Committee on 
Immunization Practices has not yet issued recommendations 
for Dengvaxia use in the United States. Other candidate vac-
cines are undergoing clinical trials.
In 2010, dengue became a nationally notifiable disease; 
state and territorial health departments report dengue cases 
to CDC through ArboNET (https://www.cdc.gov/dengue/
statistics-maps/index.html; https://wwwn.cdc.gov/nndss/
conditions/dengue/). This report describes locally acquired 
and travel-associated, laboratory-confirmed and probable 
dengue cases reported to ArboNET from the 50 states and 
District of Columbia with illness onset during January 1, 
2010–December 31, 2017.
Dengue cases were described according to the Council of State 
and Territorial Epidemiologists case definitions (7). Confirmed 
cases met the clinical criteria and had detection of 1) DENV 
nucleic acid by RT-PCR in any body fluid or tissue, 2) DENV 
antigen in tissue by a validated assay, 3) DENV NS1 antigen 
by a validated immunoassay, or 4) IgM anti-DENV antibody 
if exposure occurred in an area without evidence of other fla-
vivirus transmission. Probable dengue cases met the clinical 
criteria and were defined by detection of IgM anti-DENV 
antibody in serum if the person lived in or traveled to an area 
with transmission of another flavivirus. The infecting DENV 
was determined by molecular typing by RT-PCR (https://www.
cdc.gov/dengue/healthcare-providers/testing/molecular-tests/
index.html). Travel destinations were recorded as the areas 
visited outside the continental United States in the 14 days 
before illness onset, considered as the most likely locations of 
infection. The incidence of dengue cases among U.S. outbound 
travelers was calculated using denominator data from the 
National Travel and Tourism Office.§ Travelers to Europe were 
excluded from the denominator because of the small number 
of dengue cases reported from Europe.
During 2010–2017, a total of 5,387 dengue cases were 
reported to ArboNET, 5,009 (93%) of which were travel-
associated; 378 (7%) were locally acquired (Table 1). Two 
thirds were probable cases. Cases were equally distributed 
between males and females, and the median patient age was 
41 years. Nearly half (46%) of patients were white, and 14% 
were Asian. Among 459 cases for which the infecting DENV 
was identified, DENV-1 (308 cases, 67%) was the most com-
mon (Table 2). The largest number of dengue cases (961, 18%) 
was reported in 2016, and the smallest (254, 5%) in 2011. 
§ https://travel.trade.gov/research/monthly/departures/.
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TABLE 1. Reported number of travel-associated dengue cases, by 
state — United States, 2010–2017
State
Travel-associated cases 
No. (%)
Alabama 28 (1)
Alaska 14 (0)
Arizona 153 (3)
Arkansas 11 (0)
California 819 (16)
Colorado 49 (1)
Connecticut 55 (1)
Delaware 9 (0)
District of Columbia 27 (1)
Florida* 695 (14)
Georgia 75 (1)
Hawaii* 86 (2)
Idaho 13 (0)
Illinois 172 (3)
Indiana 48 (1)
Iowa 35 (1)
Kansas 25 (0)
Kentucky 11 (0)
Louisiana 33 (1)
Maine 14 (0)
Maryland 69 (1)
Massachusetts 38 (1)
Michigan 87 (2)
Minnesota 115 (2)
Mississippi 8 (0)
Missouri 36 (1)
Montana 19 (0)
Nebraska 13 (0)
Nevada 21 (0)
New Hampshire 13 (0)
New Jersey 249 (5)
New Mexico 11 (0)
New York* 878 (18)
North Carolina 65 (1)
North Dakota 6 (0)
Ohio 65 (1)
Oklahoma 19 (0)
Oregon 21 (0)
Pennsylvania 137 (3)
Rhode Island 24 (0)
South Carolina 40 (1)
South Dakota 10 (0)
Tennessee 47 (1)
Texas* 267 (5)
Utah 14 (0)
Vermont 19 (0)
Virginia 140 (3)
Washington 127 (3)
West Virginia 6 (0)
Wisconsin 72 (1)
Wyoming 1 (0)
Total 5,009
* In addition to travel-associated cases, these four states reported a total of 
378 locally acquired cases: Hawaii (250 cases), Florida (103), Texas (24), and 
New York (one).
The average annual number of travel-associated dengue cases 
was 626, and the average annual incidence was 16 cases per 
1 million U.S. travelers (range = 7–28).
Summary
What is already known about this topic?
The four dengue viruses are transmitted by Aedes spp. mosqui-
toes and are common causes of acute febrile illness in travelers 
visiting the tropics.
What is added by this report?
During 2010–2017, a total of 5,387 dengue cases were reported 
from U.S. states; 93% were travel-associated. Locally acquired 
cases were reported from Hawaii (250 cases), Florida (103), Texas 
(24), and New York (one).
What are the implications for public health practice?
Travelers to the tropics should protect against mosquito bites 
by using insect repellents, wearing long-sleeved shirts and long 
pants, and taking actions to keep mosquitos out of their 
residences. Clinicians should remain vigilant for and report 
suspected dengue cases to local health authorities.
Approximately one half (53%) of travel-associated cases 
were reported from four states: New York (18%), California 
(16%), Florida (14%), and Texas (5%) (Table 1). Travel history 
was reported for 96% of cases. The most frequently reported 
regions of travel were the Caribbean (33%) and Asia (29%), 
followed by Central America (14%), North America (10%) and 
South America (7%) (Table 2). The most frequently reported 
region of travel changed from the Caribbean (42%) during 
2010–2014 to Asia (35%) during 2015–2017 (Figure). The 
most frequently reported destinations with endemic transmis-
sion across all years were the countries of India (591, 12%), 
Mexico (472, 9%), and Dominican Republic (443, 9%), and 
the U.S. territory of Puerto Rico (343, 7%).
Hawaii reported the largest number of locally acquired dengue 
cases (250; 66%), followed by Florida (103; 27%), Texas (24; 
6%), and New York (one; 0.3%) (Table 1). All locally acquired 
cases in Hawaii (98%) were reported during a 2015–2016 
outbreak, whereas most cases in Florida were reported during 
outbreaks in Monroe County in 2010 (56 cases) and in Martin 
County in 2013 (17). Texas reported a small outbreak in 2013 
with most cases (21) in Cameron County.
The majority of patients with travel-associated (94%) 
and locally acquired (94%) dengue had reported symptoms 
consistent with dengue; a small percentage of patients with 
travel-associated (<1%) and locally acquired (<1%) cases had 
severe dengue. Overall, 2,176 (40%) patients with dengue 
were hospitalized, most of whom (2,119; 97%) were travelers. 
Eighteen (three per 1,000) fatal dengue cases were reported, 
all of which occurred in travelers (Table 2). The median age of 
patients with fatal dengue was 47 years (range 21–80 years). 
Region of birth was available for two of the decedents (one 
each from the Pacific and Central American regions).
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TABLE 2. Characteristics of reported travel-associated and locally acquired dengue cases — ArboNET, United States, 2010–2017
Characteristic
No. (%)
Travel-associated cases 
(n = 5,009)
Locally acquired cases 
(n = 378)
Total
(N = 5,387)
Case definition
Probable 3,539 (71) 58 (15) 3,597 (67)
Confirmed 1,470 (29) 320 (85) 1,790 (33)
Infecting DENV*
DENV-1 119 (45) 189 (96) 308 (67)
DENV-2 71 (27) 4 (2) 75 (16)
DENV-3 45 (17) 3 (2) 48 (10)
DENV-4 28 (11) 0 (0) 28 (6)
Sex†
Female 2,500 (50) 188 (50) 2,688 (50)
Male 2,508 (50) 190 (50) 2,698 (50)
Race
White 2,240 (45) 245 (65) 2,485 (46)
Asian 729 (15) 24 (6) 753 (14)
Black or African American 277 (6) 5 (1) 282 (5)
Native Hawaiian or other Pacific Islander 37 (1) 72 (19) 109 (2)
American Indian or Alaska Native 16 (0) 5 (1) 21 (0)
Asian, White 2 (0) 0 (0) 2 (0)
Asian, Native Hawaiian or other Pacific Islander 0 (0) 1 (0) 1 (0)
Unknown 1,708 (34) 26 (7) 1,734 (32)
Age group (yrs)§
0–9 129 (3) 14 (4) 143 (3)
10–19 515 (10) 46 (12) 561 (10)
20–29 887 (18) 67 (18) 954 (18)
30–39 847 (17) 43 (11) 890 (17)
40–49 897 (18) 70 (19) 967 (18)
50–59 904 (18) 57 (15) 961 (18)
60–69 574 (11) 56 (15) 630 (12)
≥70 246 (5) 24 (6) 270 (5)
Region of travel
Caribbean 1,649 (33) — 1,649 (33)
Asia 1,469 (29) — 1,469 (29)
Central America 676 (14) — 676 (14)
North America¶ 477 (10) — 477 (10)
South America 327 (7) — 327 (7)
Unknown 222 (4) — 222 (4)
Africa 89 (2) — 89 (2)
Oceania 85 (2) — 85 (2)
Europe 7 (<1) — 7 (<1)
Multiple regions 8 (<1) — 8 (<1)
See table footnotes on the next page.
Discussion
Most dengue cases reported in the 50 states and District of 
Columbia during 2010–2017 were in adults and were associ-
ated with travel to the Caribbean and Asia. Travel-associated 
cases were reported primarily from New York, California, 
Florida, and Texas. The most common travel destinations 
shifted over time, underscoring the importance of travelers 
being vigilant and reviewing current dengue trends before 
travel (https://wwwnc.cdc.gov/travel). Locally acquired cases 
occurred in four states, three of which (Florida, Hawaii, and 
Texas) also experienced local outbreaks. These data, especially 
the comparatively large outbreak in Hawaii, demonstrate the 
ongoing risk for local DENV transmission in Aedes-infested 
areas of the United States following introduction by travelers 
returning from the tropics.
Competent mosquito vectors of DENV are present in 
approximately half of all U.S. counties, and an estimated 71% 
of counties are environmentally suitable for Aedes aegypti, the 
most efficient DENV vector (8). Recent dengue outbreaks in 
the United States have been limited, likely because of lifestyle 
differences, including the use of screens in U.S. homes and air 
conditioning that limit exposure to mosquitoes (9). However, 
the trend toward more frequent travel of U.S. residents to the 
tropics increases the possibility of local dengue outbreaks, 
including in jurisdictions where local cases have not occurred 
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Characteristic
No. (%)
Travel-associated cases 
(n = 5,009)
Locally acquired cases 
(n = 378)
Total
(N = 5,387)
Clinical syndrome**
Dengue†† 4,597 (94) 353 (94) 4,950 (94)
Dengue-like illness§§ 254 (5) 24 (6) 278 (5)
Severe dengue¶¶ 46 (<1) 1 (<1) 47 (<1)
Outcome
Hospitalized 2,119 (42) 57 (15) 2,176 (40)
Died 18 (<1) 0 18 (<1)
 * Not available before 2014 (n = 459).
 † One unknown sex among travelers.
 § Ten unknown age group among travelers and one among locally acquired cases.
 ¶ 99% of patients (472) traveled to Mexico.
 ** National Notifiable Diseases Surveillance System (NNDSS) dengue definitions from 2010 and 2015. Dengue hemorrhagic fever and dengue shock syndrome cases 
were classified as severe dengue in this analysis; dengue fever and dengue fever with hemorrhage cases were classified as dengue. https://wwwn.cdc.gov/nndss/
conditions/dengue-virus-infections/case-definition/2015/.
 †† Dengue is defined by fever as reported by the patient or health care provider and the presence of one or more of the following signs and symptoms: nausea/
vomiting, rash, aches and pains (e.g., headache, retro-orbital pain, joint pain, myalgia, or arthralgia), tourniquet test positive, leukopenia (a total white blood cell 
count of <5,000/mm3), or any warning sign for severe dengue: abdominal pain or tenderness, persistent vomiting, extravascular fluid accumulation (e.g., pleural 
or pericardial effusion or ascites), mucosal bleeding at any site, liver enlargement >2 cm, or increasing hematocrit concurrent with rapid decrease in platelet count.
 §§ Dengue-like illness (59 cases) was combined with febrile illness (two), and uncomplicated fever (217); 91 cases with unknown clinical syndrome and 21 classified 
as other clinical syndrome were excluded, all of them were travel-associated.
 ¶¶ Severe dengue is defined as dengue with any one or more of the following: 1) severe plasma leakage evidenced by hypovolemic shock or extravascular fluid accumulation 
(e.g., pleural or pericardial effusion or ascites) with respiratory distress; 2) severe bleeding from the gastrointestinal tract (e.g., hematemesis or melena) or vagina 
(menorrhagia) as defined by requirement for medical intervention including intravenous fluid resuscitation or blood transfusion, or 3) severe organ involvement, 
including any of the following: elevated liver transaminases: aspartate aminotransferase or alanine aminotransferase ≥1,000 per liter (U/L), impaired level of consciousness 
or diagnosis of encephalitis, encephalopathy, or meningitis, or heart or other organ involvement including myocarditis, cholecystitis, and pancreatitis.
TABLE 2. (Continued) Characteristics of reported travel-associated and locally acquired dengue cases — ArboNET, United States, 2010–2017
FIGURE. Number of travel-associated dengue cases in U.S. residents, by reported travel destination and year of illness onset — 2010–2017
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in recent years (4). The number of travel-associated dengue 
cases peaked at approximately 900 in 2016 and could increase 
if large dengue epidemics occur in the Region of the Americas. 
Dengue surveillance is a critical public health task because of 
the presence of Aedes aegypti in many jurisdictions and the risk 
for virus introduction. Although dengue incidence in travel-
ers is low, health agencies must remain vigilant because most 
cases are asymptomatic and reported cases represent a small 
percentage of all infections.
The findings in this report are subject to at least three limi-
tations. First, reporting of dengue symptoms was incomplete. 
Second, the clinical features of dengue are similar to those for 
other acute febrile illnesses, including chikungunya and Zika 
virus disease, which complicates identification, diagnostic 
testing, and reporting of dengue patients and likely results in 
an underestimate of the true incidence of travel-associated and 
locally acquired dengue cases. In addition, the case definition 
was modified in 2015 to classify dengue hemorrhagic fever 
and dengue shock syndrome as severe dengue and dengue 
fever and dengue fever with hemorrhage as dengue (7); thus, 
annual trends might not be comparable.
Dengue is endemic in South and Central America, the 
Caribbean, Southeast Asia, and central Africa, and more than 
half of the global population live in areas that are suitable for 
DENV transmission (4). Travelers to and residents of areas 
with risk for DENV infection should implement personal 
protection measures to avoid mosquito bites, including using 
insect repellent, wearing long pants and long sleeves, and 
staying in residences with air conditioning or screened win-
dows and doors.¶ When conducting pretravel consultations, 
clinicians should include discussion of dengue risk, mosquito 
avoidance strategies, and advice about seeking health care for 
febrile illnesses occurring during or after travel. Clinicians 
should consider dengue when evaluating patients with acute 
febrile illness and recent travel to the tropics and should con-
sider recommended diagnostic testing (10). Suspected dengue 
cases should be reported to public health authorities to enable 
timely responses.
¶ https://wwwnc.cdc.gov/travel/diseases/dengue.
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